非酒精性脂肪性肝病更名带来的新思考

New thoughts about renaming nonalcoholic fatty liver disease

非酒精性脂肪性肝病(NAFLD)是一种代谢紊乱相关的多系统疾病,在肥胖和2型糖尿病(T2DM)患者中更为常见,而且与这两个共患疾病有着相似的不良结局。长期以来,NAFLD的重点强调肝脏病变和肝病相关结局,内分泌科医生按照目前糖尿病临床指南处理T2DM的同时往往忽视了对肝脏病变的筛查、诊断与处理。因此,在实际工作中,将NAFLD更名为代谢相关脂肪性肝病有着重要的现实意义。以降低肝脂肪含量为目标的防治T2DM的策略需要多学科临床与基础合作,以共同理念防治肥胖、脂肪肝、糖尿病,才能将最常见的慢性病防治落到实处。

Nonalcoholic fatty liver disease(NAFLD)is a multisystem disease involving metabolic disorder and is more common in patients with obesity and type 2 diabetes mellitus(T2DM),with similar adverse outcomes to these two comorbidities.For a long time,NAFLD has emphasized liver lesions and outcomes of liver diseases,and when treating T2DM according to the current clinical guidelines for diabetes,endocrinologists often neglect the screening,diagnosis,and treatment of liver lesions.Therefore,in clinical practice,NAFLD renamed as metabolic-associated fatty liver disease has important practical significance.Strategies for T2DM prevention and treatment aiming at reducing liver lipid content require multidisciplinary cooperation,and prevention and treatment of obesity,fatty liver disease,and diabetes with the same concepts can help to implement the prevention and treatment of the most common chronic diseases.